Evidence map›Paper›PMID 35545722›Full record

ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022

Thrombotic microangiopathy (TMA) in adult patients with solid tumors: a challenging complication in the era of emerging anticancer therapies.

Carme Font, Marta García de Herreros, Nikolaos Tsoukalas, Norman Brito-Dellan, Francis Espósito, Carmen Escalante, Thein Hlaing Oo, MASCC Hemostasis Study Group

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Carme FontMedical Oncology Department, Hospital Clinic Barcelona, Villarroel 170, 08036, Barcelona, Spain. CFONT@clinic.cat.ORCID http://orcid.org/0000-0002-3547-7373
Marta García de HerrerosMedical Oncology Department, Hospital Clinic Barcelona, Villarroel 170, 08036, Barcelona, Spain.ORCID http://orcid.org/0000-0001-8010-3584
Nikolaos TsoukalasMedical Oncology Department, 401 General Military Hospital of Athens, Athens, Greece.ORCID http://orcid.org/0000-0002-1455-1503
Norman Brito-DellanDepartment of Hospital Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5816-9285
Francis EspósitoMedical Oncology Department, Hospital Clinic Barcelona, Villarroel 170, 08036, Barcelona, Spain.ORCID http://orcid.org/0000-0002-5028-9637
Carmen EscalanteInternal Medicine Department, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-5465-8594
Thein Hlaing OoSection of Benign Hematology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5201-731X
MASCC Hemostasis Study Group
Hospital Clínic de Barcelona · ESThe University of Texas MD Anderson Cancer Center · US401 General Military Hospital of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombotic microangiopathy (TMA) is a syndrome that encompasses a group of disorders defined by the presence of endothelial damage leading to abnormal activation of coagulation, microangiopathic hemolytic anemia and thrombocytopenia, occlusive (micro)vascular dysfunction, and organ damage. TMA may occur in patients with malignancy as a manifestation of cancer-related coagulopathy itself or tumor-induced TMA (Ti-TMA) as a paraneoplastic uncommon manifestation of Trousseau syndrome. TMA can also be triggered by other overlapping conditions such as infections or more frequently as an adverse effect of anticancer drugs (drug-induced TMA or Di-TMA) due to direct dose-dependent toxicity or a drug-dependent antibody reaction. The clinical spectrum of TMA may vary widely from asymptomatic abnormal laboratory tests to acute severe potentially life-threatening forms due to massive microvascular occlusion. While TMA is a rare condition, its incidence may progressively increase within the context of the great development of anticancer drugs and the emerging scenarios in supportive care in cancer. The objective of the present narrative review is to provide a general perspective of the main causes, the key work-up clues that allow clinicians to diagnose and manage TMA in patients with solid tumors who develop anemia and thrombocytopenia due to frequent overlapping causes.

Indexed as

Anemia, HemolyticAntineoplastic AgentsNeoplasmsThrombotic MicroangiopathiesAdultHumansSyndromeAntineoplastic AgentsCancer-associated coagulopathyCancer-associated thrombocytopeniaThrombotic microangiopathy

Identifiers

PMID35545722
PMCPMC9095052
OpenAlexW4280591857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.